Closing the Gap: Personalized Approaches to Cervical Cancer Screening and Treatment

Program Overview

Despite effective screening methods for cervical cancer, many women do not have access or are not screened in a timely manner which results in delayed diagnosis and higher rates of advanced disease with lower survival rates. In recent years, immunotherapy has emerged as a new frontline treatment option that improves outcomes in women with PD-L1 positive advanced cervical cancer. In this activity you will learn about one patient’s journey with advanced cervical cancer, including her symptoms, the importance of biomarker testing, and her experience with immunotherapy.

Credit Expired

Target Audience

Oncology, OB/GYN, and Women’s Health clinicians

Educational Objectives

Upon completion of this activity, participants should be better able to:

Apply guideline-concordant cervical cancer screening strategies in vulnerable and high-risk patient populations
Utilize appropriate biomarker testing strategies in persistent, recurrent, or metastatic cervical cancer
Integrate immunotherapeutic strategies in persistent, recurrent, or metastatic cervical cancer according to approved guidelines and indications

Activity Faculty

Ritu Salani, MD, MBA

Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, CA